iiinova — where your digital self keeps evolving

Reposted by Laurence Buisseret

Alex De Caluwé @alexdecaluwe.bsky.social · 29/06/2026

Can neo-adj RT ⚡️ restore response to ICI in PD-L1-neg ER+ breast cancer? #NeoCheckRay: 3×8 Gy SBRT + anti-PD-L1 showed strong pCR signal in PD-L1 neg . On-treatment biopsies suggest TME reprogramming toward an immune-responsive state. Just published in Nature Medicine ➡️ rdcu.be/fqFY1

221

Laurence Buisseret @laubdh.bsky.social · 16/05/2025

@hoperugo.bsky.social is discussing the results of the ROSALINE trial, an IIT sponsored by the Institut Jules Bordet that evaluated ROS1 inhibition with neo-adj endocrine therapy in early ILBC #ESMOBreast25 👏🏻 @aftimosp.bsky.social & Soraia Lobo-Martins

021

Reposted by Laurence Buisseret

Philippe Aftimos, MD @aftimosp.bsky.social · 15/05/2025

Day 2 of #ESMOBreast25 in Munich. Data on ADCs will be presented during Mini Oral session 1 including results on 2️⃣ novel ADCs targeting B7H4 in HR+/HER2- and TNBC: emiltatug ledadotin and puxitatug samrotecan #ESMOAmbassadors @myesmo.bsky.social

082

Reposted by Laurence Buisseret

Philippe Aftimos, MD @aftimosp.bsky.social · 14/05/2025

Part of the Institut Jules Bordet breast cancer team at #ESMOBreast25 @laubdh.bsky.social

151

Reposted by Laurence Buisseret

Philippe Aftimos, MD @aftimosp.bsky.social · 14/05/2025

An enthusiast and militant talk by @marleenkok.bsky.social at #ESMOBreast25 on the importance of studying biomarkers for immunotherapy in breast cancer, highlighting the KN522 example #ESMOAmbassadors @myesmo.bsky.social

173

Reposted by Laurence Buisseret

Philippe Aftimos, MD @aftimosp.bsky.social · 13/05/2025

Sustainable travel 🚆 🌱 🌎 to Munich 🇩🇪 and #ESMOBreast25 #ESMOAmbassadors @myesmo.bsky.social

1102

Laurence Buisseret @laubdh.bsky.social · 27/04/2025

#AACR25 Cancer Research saves lives 🎗️

000

Reposted by Laurence Buisseret

Anouk Goudsmit @anoukgst.bsky.social · 31/01/2025

What a beautiful presentation @mybsmo by Mireille Langouo about "Lymphocyte Subpopulation Balances as a Blood Biomarker for Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitor". A study conducted @JulesBordet.

021

Reposted by Laurence Buisseret

Jon Lim, FRCP PhD @drjonlim.bsky.social · 11/12/2024

Congratulations to all #YoungOncologists - recipients of the #ESMOImmuno24 ESMO Merit Travel Grant 🏆! 📣 Special shout out to ZAYD 🙌 @zaydtippu.bsky.social - who will be presenting our work: "MANIFEST: A Multiomic Profiling Platform for Immuno-Oncology Biomarker Discovery" Go say hi - Poster: 40P!

051

Reposted by Laurence Buisseret

Anouk Goudsmit @anoukgst.bsky.social · 12/12/2024

When @marianabrandao0.bsky.social makes us travel from Geneva #ESMOImmuno24 to Tomorrowland and the Smurf Village throught a brillant discussion of 3 mini orals about treatment strategies for NSCLC patients. Thank you!

052

Laurence Buisseret @laubdh.bsky.social · 12/12/2024

Excellent discussion by @marianabrandao0.bsky.social on treatment of patients with #NSCLC #ESMOImmuno24 Insightful perspectives on recent advances!

041

Laurence Buisseret @laubdh.bsky.social · 09/12/2024

👏 to J. Stagg & D. Allard for their work revealing ENT1 as a key driver of adenosine-mediated immunosuppression. This finding offers a promising new target to enhance T cell responses against tumors. 👉full study published in Cancer Research @theaacr.bsky.social ➡️ doi.org/10.1158/0008...

040

Reposted by Laurence Buisseret

Philippe Aftimos, MD @aftimosp.bsky.social · 03/12/2024

Initiation visit this morning at Institut Jules Bordet of the EmpowHER 303 phase 3 study of anti-HER2 bispecific antibody zanidatamab in combination with chemo vs trastuzumab and chemo in HER2+ MBC. clinicaltrials.gov/study/NCT064... #bcsm

175